Entrectinib | List of Frontiers open access articles

Original Research

Published on 09 Jan 2023

Inhibition of planktonic growth and biofilm formation of Staphylococcus aureus by entrectinib through disrupting the cell membrane

in Antimicrobials, Resistance and Chemotherapy

Shanghong Liu
Yanpeng Xiong
Haitao Xiao
Jinxin Zheng
Zewen Wen
Duoyun Li
Qiwen Deng
Zhijian Yu

Frontiers in Microbiology

doi 10.3389/fmicb.2022.1106319

4,088 views
5 citations

Original Research

Published on 31 Jan 2024

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis

in Pharmacology of Anti-Cancer Drugs

Zhiwei Cui
Zhen Zhai
De Xie
Lihui Wang
Feiyan Cheng
Siyu Lou
Fan Zou
Rumeng Pan
Shixue Chang
Haoyan Yao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1329409

5,492 views
11 citations

Case Report

Published on 04 Aug 2023

Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer

in Head and Neck Cancer

Etsuko Moriyama
Sachiko Nagasu
Toshimitsu Tanaka
Yasutaka Shimotsuura
Takeharu Ono
Hirohito Umeno
Jun Akiba
Akihiko Kawahara
Fumihiko Fujita
Takumi Kawaguchi

Frontiers in Oncology

doi 10.3389/fonc.2023.1247435

4,066 views
7 citations

Case Report

Published on 29 Apr 2021

Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor

in Pediatric Urology

Paolo Bonvini
Elisabetta Rossi
Angelica Zin
Mariangela Manicone
Riccardo Vidotto
Antonella Facchinetti
Lucia Tombolan
Maria Carmen Affinita
Luisa Santoro
Rita Zamarchi

Frontiers in Pediatrics

doi 10.3389/fped.2021.652583

3,470 views
5 citations

Original Research

Published on 13 Feb 2025

Entrectinib can induce nerve cell damage by inhibiting PI3K-AKT and TGF-β signaling pathways

in Predictive Toxicology

Qingshan Tang
Jiachen Dong
Feng Zhang
Dan Zhao
Qi Yang
Jiayu Wen
Yuhao Sun
Jifu Wei
Zhixian Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1489210

3,815 views
4 citations

Case Report

Published on 07 Nov 2022

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib

in Thoracic Oncology

Chiara Lazzari
Lorenza Pecciarini
Claudio Doglioni
Federica Pedica
Ana Maria Samanes Gajate
Alessandra Bulotta
Vanesa Gregorc
Maria Giulia Cangi

Frontiers in Oncology

doi 10.3389/fonc.2022.1038774

4,505 views
8 citations

Original Research

Published on 14 Jun 2022

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach

in Regulatory Science

Jorn Mulder
Odile C. van Stuijvenberg
Paula B. van Hennik
Emile E. Voest
Anna M. G. Pasmooij
Violeta Stoyanova-Beninska
Anthonius de Boer

Frontiers in Medicine

doi 10.3389/fmed.2022.893400

5,096 views
7 citations

Case Report

Published on 09 Oct 2023

NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report

in Molecular and Cellular Oncology

Emanuela Palmerini
Giorgio Frega
Marco Gambarotti
Tommaso Frisoni
Marilena Cesari
Alberto Bazzocchi
Marco Miceli
Davide Maria Donati
Stefano Fanti
Cristina Nanni

Frontiers in Oncology

doi 10.3389/fonc.2023.1252359

3,774 views
8 citations

Case Report

Published on 11 Dec 2024

Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report

in Thoracic Oncology

Jian Wang
Bingyue Liu
Qinhong Zheng
Ruoshui Xiao
Jianxin Chen

Frontiers in Oncology

doi 10.3389/fonc.2024.1507658

2,081 views
5 citations

Case Report

Published on 16 Oct 2025

Case Report: Malignant peritoneal mesothelioma with TFG-ROS1 fusion responds to crizotinib

in Cancer Molecular Targets and Therapeutics

Wei Ye
Peng Li
Cong Fu
Tong Zhou

Frontiers in Oncology

doi 10.3389/fonc.2025.1617457

1,773 views

Case Report

Published on 18 Apr 2024

Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report

in Thoracic Oncology

Dan Li
Yue Zhu
Jincheng Song
Dafu Yang
Saiqiong Cui
Xin Liu
Le Wang
Jiangyan Zhang
Evenki Pan
Zhaoxia Dai

Frontiers in Oncology

doi 10.3389/fonc.2024.1339511

2,720 views
1 citation

Case Report

Published on 10 Jan 2023

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib

in Cancer Molecular Targets and Therapeutics

Wen-Chi Wu
Ming-Huang Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.1031396

3,065 views
1 citation

Case Report

Published on 28 Apr 2023

Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma

in Head and Neck Cancer

Qing-Xiang Yu
Wen-Jun Zhao
He-Yue Wang
Lei Zhang
Lan Qin
Lei Zhang
Jian-li Han

Frontiers in Oncology

doi 10.3389/fonc.2023.1123812

3,623 views
2 citations

Case Report

Published on 23 Sep 2025

Case Report: Metastasis to pleura and mediastinal lymph nodes from breast secretory carcinoma: 10 years follow-up

in Breast Cancer

Fengbo Huang
Jing Zhao
Jie Lian
Bo Hong
Xiaoyan Yu
Xiaojing Ma
Jiabin Lai
Wei Qian
Jinglian Tu
Fuming Qiu

Frontiers in Oncology

doi 10.3389/fonc.2025.1641375

2,285 views

Case Report

Published on 01 Aug 2025

ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report

in Intensive Care Cardiovascular Medicine

Qi Yujuan
Ma Xiaozhong
Wu Zhenhua
Bai Yunpeng

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2025.1626318

2,653 views
1 citation

Original Research

Published on 14 Jun 2021

Genomic Landscape of Head and Neck Squamous Cell Carcinoma Across Different Anatomic Sites in Chinese Population

in Cancer Genetics and Oncogenomics

Yunhe Ju
Xingrao Wu
Huizhen Wang
Bin Li
Qing Long
Dadong Zhang
Hao Chen
Nianqing Xiao
Fugen Li
Shiwen Zhang

Frontiers in Genetics

doi 10.3389/fgene.2021.680699

8,980 views
18 citations

Articles

Inhibition of planktonic growth and biofilm formation of Staphylococcus aureus by entrectinib through disrupting the cell membrane

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis

Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer

Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor

Entrectinib can induce nerve cell damage by inhibiting PI3K-AKT and TGF-β signaling pathways

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach

NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report

Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report

Case Report: Malignant peritoneal mesothelioma with TFG-ROS1 fusion responds to crizotinib

Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib

Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma

Case Report: Metastasis to pleura and mediastinal lymph nodes from breast secretory carcinoma: 10 years follow-up

ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report

Genomic Landscape of Head and Neck Squamous Cell Carcinoma Across Different Anatomic Sites in Chinese Population